Bioharvest Sciences Inc BHST

$1.72 +0.04 (2.38%)

Valuation

Market cap
33,740,000
Revenue TTM
$34,510,000
Net income TTM
$-11,140,000
PE ratio
0.00
Forward PE
—
Profit margin
-32.28%
Debt to equity
0.13

Trading

Volume
25,300
Avg volume
29,718
Day's range
$1.65 – $1.83
Shares out
19,616,000
Stochastic %K
60%
Beta
1.04
Analysts
Strong Sell
Price target
$10.50

Price

Company profile

BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical...

Show more

BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.

Industry
Packaged Foods
Sector
Consumer Defensive
Phone
604 689 5722
Website
https://www.bioharvest.com
Address
1140-625 Howe Street, Vancouver, Canada

Latest news

No headlines yet.